

***Fiscal Year 2024 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPCTA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • <i>Preproposal submission is required; application submission is by invitation only.</i> • Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition in the Topic Area(s) of interest. • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • Two options will be offered: <ul style="list-style-type: none"> ○ <u>Planning Phase with Clinical Trial Option:</u> Provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded. ○ <u>Clinical Trial Only Option:</u> Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission. 	<p><u>Clinical Trial:</u></p> <ul style="list-style-type: none"> • A funding limit is not defined; requested funding must be appropriate for the scope of work proposed. • The maximum period of performance for the clinical trial is 4 years. <p><u>Planning Phase with Clinical Trial Option:</u></p> <ul style="list-style-type: none"> • The maximum allowable funding for the Planning Phase period of performance is \$500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance for the planning phase is 12 months. • The maximum period of performance for the clinical trial is 4 years. 	<p>Pre-Application (Preproposal): May 13, 2024 5:00 p.m. Eastern time</p> <p>Application: August 19, 2024 11:59 p.m. Eastern time</p>
<p>Discovery Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPDA</p>	<p>Postdoctoral fellow or clinical fellow (or equivalent) and above</p>	<ul style="list-style-type: none"> • Supports innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies or applications. • Not intended to support the logical progression of an already established line of questioning. • <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$275,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): May 6, 2024 5:00 p.m. Eastern time</p> <p>Application: May 23, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPIIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports research that will make an important contribution toward research, patient care and/or quality of life for a disease of condition in the Topic Area(s) of interest. <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$1.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 6, 2024 5:00 p.m. Eastern time</p> <p>Application: May 23, 2024 11:59 p.m. Eastern time</p>
<p>Impact Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPIPA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from real-world environment to foster clinical applicability in the Topic Area(s) of interest. Partnering Principal Investigator Option available. <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$2.0 million for direct costs for single investigators and \$2.6 million for partnering investigators. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 13, 2024 5:00 p.m. Eastern time</p> <p>Application: June 6, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Lifestyle and Behavioral Health Interventions Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPLBIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance and public health that will enhance patient experience and improve outcomes. Projects may include clinical research or clinical trials for <i>interventions that do not require regulation by the FDA</i>. Encourages patient advocate participation in the research team. <i>Animal studies will not be funded.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$3.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 13, 2024 5:00 p.m. Eastern time</p> <p>Application: June 6, 2024 11:59 p.m. Eastern time</p>
<p>Technology/Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PRMRPTTDA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life. Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$4.0 million for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 13, 2024 5:00 p.m. Eastern time</p> <p>Application: June 6, 2024 11:59 p.m. Eastern time</p>